Precigen Webcast on June 3rd for PRGN-2012 Study Results in Recurrent Respiratory Papillomatosis from 2024 ASCO Meeting

Precigen, Inc., a biopharmaceutical company known for its groundbreaking work in gene and cell therapies, has announced an upcoming webcast on June 3, 2024, at 6:00 PM CT/7:00 PM ET. This webcast will follow the presentation of pivotal study results for PRGN-2012, a treatment for recurrent respiratory papillomatosis (RRP), at the American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, titled "PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients," will be delivered by Dr. Scott M. Norberg from the National Cancer Institute. Viewers can register for the webcast through Precigen’s website, where an archived recording will also be available post-event.

Precigen is focused on developing next-generation gene and cell therapies, particularly for immuno-oncology, autoimmune disorders, and infectious diseases. Their approach uses cutting-edge precision technology to create affordable and effective biotherapeutics. The company’s innovation engine is driving a diverse pipeline of therapies, from preclinical stages to clinical proof-of-concept and commercialization.

Central to Precigen's efforts is their proprietary AdenoVerse platform, which includes a library of adenovectors designed for efficient gene delivery. These vectors, particularly their gorilla adenovectors, outperform current alternatives by inducing strong and durable immune responses and allowing for repeated administrations. The platform's superior performance and high-yield manufacturing leverage Precigen's UltraVector technology to develop advanced investigational therapies for complex diseases.

Currently, Precigen's AdenoVerse is being evaluated in several clinical trials. These include a Phase 1/2 study of PRGN-2009, both alone and combined with other treatments, for HPV-associated cancers. Additionally, there are Phase 2 studies exploring PRGN-2009 in combination with pembrolizumab for newly diagnosed HPV-associated oropharyngeal squamous cell carcinoma and recurrent or metastatic cervical cancer. PRGN-2012 is also under investigation in a Phase 1/2 study for RRP and has received Orphan Drug Designation and Breakthrough Therapy Designation from the FDA, as well as Orphan Drug Designation from the European Commission.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!